Clinical trials
Ovarian cancer clinical trials
Cancer that starts in the ovaries, often found at a later stage. We’re tracking 607 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07741968Recruiting
Online program to ease fear of cancer returning
This study tests an online program designed to help women with advanced or certain types of breast or gynecologic cancer manage their fear of the disease progressing or returning. The program aims to reduce anxiety and improve quality of life.
Arcadia, CaliforniaAges 18 years+ - NCT01870752Recruiting
Transplanting frozen ovarian tissue to help you try for pregnancy
This trial studies whether thawed, previously frozen ovarian tissue can be transplanted to help people with ovarian insufficiency become pregnant. It may help if you already have cryopreserved ovarian tissue stored and your care team feels you’re a good candidate for the procedure.
Philadelphia, PennsylvaniaAges 18–45 - NCT06458712RecruitingPhase 1
Testing a new drug for advanced cancers with gene changes
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
New Haven, ConnecticutAges 18 years+ - NCT05830929Recruiting
Freezing ovarian tissue and later putting it back
This study tests a way to protect future fertility in young people who need cancer treatment. It freezes ovarian tissue before treatment and, if appropriate, later returns it to the body to help restore hormone production and possible future pregnancy.
Hong KongAges 1 month–35 years - NCT05950464RecruitingPhase 1
Dose study of two targeted drugs for recurrent ovarian cancer
This Phase 1 trial tests different doses of two study drugs (M1774 and ZEN-3694) for recurrent ovarian cancer and some recurrent endometrial cancers. It aims to find a safe dose and see how well the treatment works, especially in cancers with certain tumor features.
Augusta, GeorgiaAges 18 years+ - NCT03382158Recruiting
Learn about DICER1-related tumors through a patient registry
This registry collects information about people with known or suspected DICER1-related conditions, including certain rare chest and other tumor types. It helps doctors and researchers understand these conditions better and may support future studies.
Minneapolis, MinnesotaAges birth–100 years - NCT04969835RecruitingPhase 1
Safety and early response study of AVA6000 for solid tumors
This Phase 1 study tests AVA6000 in people with certain solid tumor cancers, mainly to check safety and how the body processes the drug. It also looks for early signs of tumor response to see if it might help further in later studies.
New York, New YorkAges 18 years+ - NCT06505057Recruiting
Freezing and re-implanting ovarian tissue for young cancer patients
This study tests a method to preserve fertility by freezing ovarian tissue before cancer treatment and later re-implanting it. It may help young women and girls who face infertility from their cancer therapy.
Hong KongAges 12–18 - NCT07115043RecruitingPhase 1/Phase 2
Study of AZD6750 for advanced solid tumors
This trial tests a new drug called AZD6750 for people with advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Grand Rapids, MichiganAges 18 years+ - NCT06727487Recruiting
Ovarian suppression and exercise in young breast cancer patients
This trial tests whether adding a supervised exercise program helps women with hormone-positive breast cancer who are receiving ovarian suppression therapy. It looks at how exercise affects treatment side effects, quality of life, and long-term health.
MadridAges 18–45 - NCT06161025RecruitingPhase 2/Phase 3
Raludotatug Deruxtecan for resistant ovarian cancer
This study tests a new drug called Raludotatug Deruxtecan (R-DXd) for people with ovarian, fallopian tube, or primary peritoneal cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if R-DXd can shrink tumors or slow cancer growth.
Anchorage, AlaskaAges 18 years+ - NCT04196257RecruitingPhase 1
Early-dose trial of BP1001-A for advanced or recurrent solid tumors
This Phase 1 trial studies BP1001-A in people with advanced or recurring solid cancers to find a safe dose and learn how the treatment works. You may be asked for tumor biopsies before and possibly after treatment to see how the cancer responds.
Silver Spring, MarylandAges 18 years+ - NCT05902988RecruitingPhase 1/Phase 2
Study of VLS-1488 for advanced cancers
This early-phase study tests VLS-1488, a new cancer medicine, in people with advanced cancers that have limited treatment options. It may help by finding a safe dose and whether it can shrink or control tumors.
Los Angeles, CaliforniaAges 18 years+ - NCT05985655RecruitingPhase 1/Phase 2
Study of GTAEXS617 for advanced solid tumors
This trial tests a new drug called GTAEXS617 for adults with certain advanced solid tumors that have not responded to standard treatments. It aims to see if the drug is safe and effective.
Los Angeles, CaliforniaAges 18 years+ - NCT06380816RecruitingPhase 1/Phase 2
Study of UCB4594 for advanced cancers with HLA-G marker
This trial tests an experimental drug called UCB4594 for people with certain advanced cancers that have not responded to standard treatments. The goal is to see if the drug is safe and effective against tumors that have a specific marker called HLA-G.
LondonAges 18 years+ - NCT06556342Recruiting
Testing a new contrast agent for ovarian mass ultrasound
This trial is testing an investigational contrast agent (FRD001) to see if it improves ultrasound images of suspicious ovarian masses. The goal is to help doctors better tell if a mass is cancerous or not.
Wuhan, HubeiAges 18–75 - NCT04389632RecruitingPhase 1
Sigvotatug vedotin for advanced solid tumors that spread
This early-stage study tests a drug called sigvotatug vedotin in people with advanced solid cancers that cannot be removed or have spread. It aims to see how well the treatment works and what side effects it causes.
Anchorage, AlaskaAges 18 years+ - NCT02637934RecruitingPhase 1
PET scan tracer study for ovarian or related cancers
This early study tests a radioactive tracer (given as an injection) and tracks how it moves through the body using PET/CT scans. It may help doctors better understand how this tracer behaves in cancers of the ovaries, fallopian tubes, or the lining of the abdomen.
Philadelphia, PennsylvaniaAges 18 years+ - NCT04919629RecruitingPhase 2
Tested treatments for recurrent ovarian cancer with fluid buildup
This Phase 2 study tests whether adding two medicines—APL-2 plus pembrolizumab or pembrolizumab plus bevacizumab—works better than bevacizumab alone for recurrent ovarian, fallopian tube, or primary peritoneal cancer. It also focuses on people who have symptoms from cancer-related fluid (ascites or pleural effusion).
Buffalo, New YorkAges 18 years+ - NCT05538091RecruitingPhase 2
Testing vismodegib plus atezolizumab for platinum-resistant ovarian cancer
This Phase 2 trial tests whether combining vismodegib with atezolizumab can slow or shrink platinum-resistant ovarian, fallopian tube, or primary peritoneal cancer. It targets cancers that grow again within 6 months after platinum chemotherapy.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT05875155Recruiting
Saving eggs by freezing ovarian tissue during cancer or surgery care
This trial looks at freezing ovarian tissue to help protect future fertility for people who may lose ovarian function from medical treatments or ovarian surgery. It may help you preserve the chance to have children later when egg or embryo freezing alone isn’t an option.
Pittsburgh, PennsylvaniaAges Up to 39 years - NCT06969833Recruiting
Study of Ovarian, Peritoneal, or Fallopian Tube Cancer
This study will collect medical information from people with advanced ovarian, peritoneal, or fallopian tube cancer. The goal is to learn more about these cancers and improve future treatments.
LilleAges 18 years+ - NCT06422455Recruiting
Genetic testing for underserved cancer patients
This study offers free genetic testing to cancer patients and their healthcare providers. It aims to help people who may not have easy access to genetic testing understand their cancer risk.
Los Angeles, CaliforniaAges 18 years+ - NCT05920798RecruitingPhase 1/Phase 2
Vaccine treatment plus pembrolizumab for recurrent ovarian cancer
This Phase 1/2 trial tests a new cancer vaccine therapy combined with pembrolizumab (an immunotherapy) to treat advanced, recurrent ovarian, fallopian tube, or primary peritoneal cancer. It may help your immune system recognize and attack the cancer, especially if your tumor has a specific target called FRα.
Scottsdale, ArizonaAges 18 years+
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for ovarian cancer?
- Yes. Clin2 currently lists 607 recruiting ovarian cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a ovarian cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a ovarian cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.